Matches in Nanopublications for { ?s ?p "[To effectively target dyslipidemia to reduce the risk of cardiovascular disease, it may be beneficial to activate the peroxisome proliferator-activated receptors (PPARs) PPARalpha and PPARdelta simultaneously through a single molecule.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 4 of
4
with 100 items per page.
- assertion description "[To effectively target dyslipidemia to reduce the risk of cardiovascular disease, it may be beneficial to activate the peroxisome proliferator-activated receptors (PPARs) PPARalpha and PPARdelta simultaneously through a single molecule.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[To effectively target dyslipidemia to reduce the risk of cardiovascular disease, it may be beneficial to activate the peroxisome proliferator-activated receptors (PPARs) PPARalpha and PPARdelta simultaneously through a single molecule.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP618273.RAuIYKqgdLArRe7afeubLE57mYjj4UsoFEYQxe_qEWilE130_assertion description "[To effectively target dyslipidemia to reduce the risk of cardiovascular disease, it may be beneficial to activate the peroxisome proliferator-activated receptors (PPARs) PPARalpha and PPARdelta simultaneously through a single molecule.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618273.RAuIYKqgdLArRe7afeubLE57mYjj4UsoFEYQxe_qEWilE130_provenance.
- NP618275.RAOHcTm1nVe-kIR3TY3yK5l9rwu3ZSGmsjMPRY-MFHVwg130_assertion description "[To effectively target dyslipidemia to reduce the risk of cardiovascular disease, it may be beneficial to activate the peroxisome proliferator-activated receptors (PPARs) PPARalpha and PPARdelta simultaneously through a single molecule.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP618275.RAOHcTm1nVe-kIR3TY3yK5l9rwu3ZSGmsjMPRY-MFHVwg130_provenance.